Acute pancreatitis
Conditions
Interventions
control group:placebo control group
experimental group:Parecoxib group
Sponsors
The first affiliated hostipal of nanchang university
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Aged 18-75, gender not limited; 2.The diagnostic criteria for acute pancreatitis are met when two of the following three criteria are present: (1) characteristic symptoms of acute pancreatitis, including persistent epigastric pain; (2) serum amylase and/or lipase levels >= 3 times the upper limit of normal; and (3) characteristic imaging findings of acute pancreatitis, such as CT, ultrasound, or MRI. 3.Blood triglyceride >= 11.30mmol/L; 4.= 2 as the predictive criterion); 6.Voluntary participation in the study and signing of the informed consent form;
Exclusion criteria
Exclusion criteria: 1.The biliary cause should meet one of the following three points: (1) common bile duct stones or common bile duct dilation (>8mm,>1.2mm in cholecystectomy); (2) serum bilirubin>40umol/L; (3) gallstones accompanied by AKP or ALT higher than 3 times the upper limit of normal. 2.Concomitant alcohol-related etiology: alcohol consumption >= 50g/day for>5 years; 3.Pregnant and breastfeeding women; 4.Individuals with a history of hypersensitivity to parecoxib or other active pharmaceutical ingredients used in the study; 5.NSAIDs are contraindicated in patients with active gastrointestinal bleeding, peptic ulcers, or other severe digestive system disorders such as cirrhosis with esophageal varices, ulcerative colitis, or Crohn's disease. 6.Patients with severe underlying diseases or malignancies in vital organs such as the heart, lungs, brain, and kidneys; 7.Individuals with mental disorders or other conditions who cannot participate in clinical research; 8.use of NSAIDs and other similar drugs (e.g. glucocorticoids) within 2 weeks before trial entry;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of early persistent organ failure, defined as the absence of organ failure before randomization , with new-onset organ failure occurring within 7 days after randomization and lasting>48; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of infected pancreatic necrosis;Case fatality rate;new-onset renal failure;New-onset respiratory failure;CT Pancreatic Severity Index;SIRS grade;safety endpoint;APACHEII score;Follow-up for 6 months;Intra-abdominal hemorrhage;Sepsis;Intensive care time;hospitalization expenses;Serum inflammatory markers;New-onset circulatory failure;total length of stay;acute gastrointestinal injury (AGI) score;Portal vein system thrombosis;Gastrointestinal fistula:; | — |
Countries
China
Contacts
Public ContactWenhua He
The first affiliated hostipal of nanchang university
Outcome results
None listed